Bill
Bill > SB665
NH SB665
NH SB665Relative to pharmacy benefits managers, managed care laws, notice of drug pricing optionsand pharmacy benefit manager business practices.
summary
Introduced
02/04/2026
02/04/2026
In Committee
05/01/2026
05/01/2026
Crossed Over
03/27/2026
03/27/2026
Passed
Dead
05/14/2026
05/14/2026
Introduced Session
2026 Regular Session
Bill Summary
This bill: I. Requires written agreement to be formed between pharmacy benefits managers and health carriers before benefits managers can operate. II. Amends pharmacy benefits manager reporting and examination requirements. III. Raises the value of the maximum administrative fine that can be levied for violations of the state's pharmacy benefits manger laws. IV. Requires pharmacies to make efforts to notify consumers of their right to request the lowest available price for prescription drugs. V. Prohibiting health carriers or pharmacy benefit managers from penalizing, requiring, or providing, financial incentives to covered persons as incentives to use specific retail, mail order pharmacy, or another network pharmacy provider that is an affiliate of the pharmacy benefit manager.
AI Summary
This bill aims to increase transparency and fairness in prescription drug pricing by requiring pharmacies to inform consumers of their right to request the lowest available price for their medications and to provide information on various pricing options, including cash prices and discounts. It also mandates that pharmacy benefit managers (PBMs), which manage prescription drug benefits for health carriers, must have written agreements with health carriers outlining their duties and fiduciary responsibilities, and are subject to increased oversight and higher administrative fines for violations, with the maximum fine for violations of state PBM laws being raised to $10,000 per day. Furthermore, the bill prohibits health carriers or PBMs from steering patients towards affiliated pharmacies through financial incentives or penalties, and requires PBMs to report detailed financial information about rebates and fees collected from pharmaceutical manufacturers to the state. The bill also extends the timeframe for notifying consumers about changes to drug formularies and increases the font size for such notices, and clarifies that denials of exception requests for medically necessary drugs are considered adverse determinations.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (17)
Denise Ricciardi (R)*,
Regina Birdsell (R),
Sharon Carson (R),
Donovan Fenton (D),
Loren Foxx (D),
Bill Gannon (R),
Katelyn Kuttab (R),
Patrick Long (D),
Wayne MacDonald (R),
Mark McConkey (R),
Howard Pearl (R),
Rebecca Perkins Kwoka (D),
Tara Reardon (D),
David Rochefort (R),
Catherine Rombeau (D),
Cindy Rosenwald (D),
David Watters (D),
Last Action
Inexpedient to Legislate: Motion Adopted Voice Vote 05/14/2026 House Journal 13 (on 05/14/2026)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...